Shattuck Labs (Shattuck Labs) ROCE % : -57.24% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shattuck Labs ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Shattuck Labs's annualized ROCE % for the quarter that ended in Mar. 2024 was -57.24%.

Shattuck Labs ROCE % Historical Data

The historical data trend for Shattuck Labs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shattuck Labs ROCE % Chart

Shattuck Labs Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-69.35

-20.68

-14.94

-45.48

-55.99

Shattuck Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-50.67	-59.87	-88.44	-57.32	-57.24

Shattuck Labs ROCE % Calculation

Shattuck Labs's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-91.957	/	( ( (205.324 - 24.965)	+	(159.564 - 11.453) )	/ 2 )
	=	-91.957	/	( (180.359	+	148.111)	/ 2 )
	=	-91.957	/	164.235
	=	-55.99 %

Shattuck Labs's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-80.176	/	( ( (159.564 - 11.453)	+	(146.335 - 14.329) )	/ 2 )
	=	-80.176	/	( ( 148.111	+	132.006 )	/ 2 )
	=	-80.176	/	140.0585
	=	-57.24 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Shattuck Labs (NAS:STTK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Shattuck Labs ROCE % Related Terms

Thank you for viewing the detailed overview of Shattuck Labs's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shattuck Labs (Shattuck Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shattuck Labs Inc (NAS:STTK) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701

Website

https://www.shattucklabs.com

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Executives

Andrew R Neill	officer: See Remarks	1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703
Stephen Stout	officer: See Remarks	C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Abhinav A. Shukla	officer: Chief Technical Officer	500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Carrie Brownstein	director	500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Erin Ator Thomson	officer: General Counsel	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Josiah Hornblower	director, 10 percent owner, officer: Chairman	3317 BOWMAN AVE, AUSTIN TX 78703
Taylor Schreiber	director, officer: Chief Executive Officer	100 EUROPA DRIVE, CHAPEL HILL NC 27517
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Helen M Boudreau	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Neil W Gibson	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Tyler Brous	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Casi Deyoung	officer: Chief Business Officer	C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Arundathy N. Pandite	officer: Chief Medical Officer	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Victor Stone	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703